Barely Significant
← all excerpts

Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study.

Neurotherapeutics · 2021 · PMC8423982 · PMID 33624184

Europe PMCDOI
2
hedged sentences
0.0380
closest p · 0.8× alpha
0.0380
boldest claim

The sentences

nominally significantp = 0.038actually significant
A nominally significant LS mean difference of 30.8 m ( p = 0.038) between reldesemtiv 450 mg bid and placebo was observed up to 4 weeks after dosing at the follow-up visit.

also in 7,732 other papers

showed a trendno p-value reported
In a post hoc analysis of baseline features, a trend to predicting a response in MEP was limited to a lower baseline MEP value and only older age showed a trend to predicting a response in the 6MWD.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.